STAT-3 dephosphorylation induced by Sorafenib has been described in in vitro studies of human medulloblastomas [12] and esophageal adenocarcinomas, [13] and in vivo study of cholangiocarcinomas [14]. This evidence concerns the gene STAT3 and esophageal adenocarcinoma.